Patients with high ER‐GREB1 co‐expressing tumours had favourable survival outcomes and response to ET when compared to ER+ BC lacking GREB1 expression, highlighting the role of GREB1 for a functional ER pathway.80 Here, GREB1 is linked to breast cancer.